Irinotecan pharmacokinetics;Pharmacocinetique de l'irinotecan

Bulletin du Cancer

Volumn 85, Issue SPEC. ISS. DEC., 1998, Pages 11-20

  Chabot, Guy G ^a   Robert, Jacques ^b   Lokiec, François ^c   Canal, Pierre ^d  

^a SAINT LOUIS HOSPITAL   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

CPT11; Irinotecan; Metabolism; Pharmacodynamics; Pharmacokinetics

Indexed keywords

7 ETHYL 10 [4N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXY CAPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; IRINOTECAN; UNCLASSIFIED DRUG; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; PLASMA PROTEIN; PRODRUG; TUMOR PROTEIN;

AREA UNDER THE CURVE; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; LIVER METABOLISM; NONHUMAN; REVIEW; ANIMAL; BIOLOGICAL MODEL; BIOTRANSFORMATION; BODY FLUID COMPARTMENT; DRUG ANTAGONISM; DRUG DETOXIFICATION; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; HALF LIFE TIME; LIVER; METABOLISM; MOUSE; NEOPLASM; RAT; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOTRANSFORMATION; BLOOD PROTEINS; BODY FLUID COMPARTMENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HALF-LIFE; HUMANS; LIVER; METABOLIC DETOXICATION, DRUG; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PRODRUGS; RATS; TISSUE DISTRIBUTION;

EID: 0032249640     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1996 ; 88 : 3888-90.
2. Potmesil M. Camptothecins : from bench research to hospital wards. Cancer Research 1994 ; 54 : 1431-9.
3. Wall ME, Wani MC. Camptothecin and analogs : from discovery to clinic. In : Camptothecins : new anticancer agents. M Potmesil and H Pinedo, ed. CRC Press, Inc., Boca Raton, Florida, pages 21-41, 1995.
4. Wall ME, Wani MC. Camptothecin : discovery to clinic. In : The camptothecins, from discovery to the patient. P Pantazis, BC Giovanella, ML Rothenberg, eds. Annals of the New York Academy of Sciences, volume 803. New York, N.Y., pages 1-12, 1996.
5. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988 ; 48 : 1722-6.
6. Jaxel C, Kohn K, Wani MC, et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I. Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res 1989 ; 49 : 1465-9.
7. Hsiang YH, Liu LF, Wall ME, et al. DXA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989 ; 49 : 4835-9.
8. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomcrase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989 ; 246 : 1046-8.
9. Potmesil M, Hsiang YH, Liu LF, et al. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988 ; 48 : 3537-43.
10. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987 ; 47 : 5944-7.
11. Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl)camptothecin analogues : inhibition of topoisomerase I and antitumor activity. J Med Chem 1991 ; 34 : 98-107.
12. Wani MC, Nicholas AW, Wall ME. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. J Med Chem 1986 ; 29 : 2358-63.
13. Hertzberg RP, Caranfa MJ, Hecht S. On the mechanism of topoisomerase I inhibition by camptothecin : evidence for binding to an enzyme-DNA complex. Biochemistry 1989 ; 28 : 4629-38.
14. Kessel D, Bosmann HB, Lohr K. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochem. Biophys Acta 1972 ; 269 : 210-6.
15. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985 ; 54 : 665-97.
16. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989 ; 58 : 351-75.
17. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN38, a metabolite of the camptothecin derivative, CPT11, in the antitumor effect of CPT11. Cancer Res 1991 ; 51 : 4187-91.
18. Ogasawara H, Nishio K, Kanzawa F, et al. Intracellular carboxylesterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT11. Jpn J Cancer Res 1995 ; 86 : 124-9.
19. Jansen WJ, Zwaer B, Hulscher ST, et al. CPT11 in human colon cancer cell lines and xenografts : characterization of cellular sensitivity determinants. Int J Cancer 1997 ; 70 : 335-40.
20. Suzuki A, Kato M. Chemotherapeutic agenr CPT11 induces the new expression of the apoptosis initiator to the cytoplasm. Exp Cell Res 1996 ; 227 : 154-9.
21. Woessner RD, Eng WK, Hofmann FA, et al. Camptothecin hyperresistant P388 cells : drug-dependent reduction in topoisomerase I content. Oncol Res 1992 ; 4 : 481-8.
22. Gupta RS, Gupta R, Eng B, et al. Camptothecin-resistant mutants of chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 1988 ; 48 : 6404-10.
23. Kanzawa F, Sugimoto Y, Minato K, et al. Establishment of a camptothecin analogue (CPT11)-resistant cell line of human small cell lung cancer : characterization and mechanism of resistance. Cancer Res 1990 ; 50 : 5919-24.
24. Sugimoto Y, Tsukahara S, Oh-Hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 1990 ; 50 : 6925-30.
25. Tamura H, Kohchi C, Yamada R. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 1991 ; 51 : 1129-36.
26. Goldwasser F, Bae I, Valenti M, et al. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995 ; 55 : 2116-21.
27. Chen AY, Yu C, Potmesil M, et al. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells, Cancer Res. 1991 ; 51 : 6039-44.
28. Takeda S, Shimazoe T, Kuga H, et al. Camptothecin analog (CPT11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN38, an active metabolite of CPT11. Biochem Biophys Res Commun 1992 ; 188 : 70-7.
29. Onishi Y, Oguro M, Kizaki H. A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT11. Cancer Chemother Pharmacol 1997 ; 39 : 473-8.
30. Kawato Y, Furuta T, Aonuma M, et al. Antitumor activity of a camptothecin derivative, CPT11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991 ; 28 : 192-8.
31. Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT11) in mice. Anti-Cancer Drugs 1996 ; 7 : 437-60.
32. Tanizawa A, Fujimori A, Fugimori Y, et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of eamptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994 ; 86 : 836-42.
33. Lavelle F, Bissery MC, André S, et al. Preclinical evaluation of CPT11 and its active metabolite SN-38. Semin Oncol 1996 ; (1 suppl. 3) : 11-20.
34. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts : lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993 ; 53 : 2823-9.
35. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996 ; 74 : 537-45.
36. Komuro H, Li P, Tsuchida Y, et al. Effects of CPT11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med Pediatr Oncol 1994 ; 23 : 487-92.
37. Hare CB, Elion GB, Houghton PJ. et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 1997 ; 38 : 187-91.
38. Tsuruo T, Matsuzaki T, Matsushita M, et al. Antitumor effect of CPT11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988 ; 21 : 71-4.
39. Taguchi T, Wakui A, Hasegawa K. Phase I clinical study of CPT11. Research Group of CPT11. Jpn J Cancer Chemother 1990 ; 17 : 115-20.
40. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advance non-small cell lung cancer. J Natl Cancer Inst 1991 ; 83 : 1164-8.
41. Ohe Y, Sasaki Y, Shinkai T, et al. Phase I study and pharmacokinetics of CPT11 with 5-day continuous infusion. J Natl Cancer Inst 1992 ; 84 : 972-4.
42. Rothenberg ML, Kuhn JG, Burris III HA, et al. Phase I and pharmacokinetic trial of weekly CPT11. J Clin Oncol 1993 ; 11 : 2194-204.
43. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxycamptothecin (CPT11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994 ; 54 : 427-36.
44. Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT11) administered daily for three consecutive days every 3 weeks in patients with advanced solid tumors. Ann Oncol 1995 ; 6 : 133-40.
45. de Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinorecan administered on a weekly schedule in cancer patients. Cancer Res 1994 ; 54 : 4347-54.
46. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995 ; 13 : 210-21.
47. Gandia D, Abigerges D, Armand JP, et al. CPT11-induced cholinergic effects in cancer patients. J Clin Oncol 1993 ; 11 : 196-7 (letter).
48. Merrouche Y, Extra JM, Abigerges D, et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients : a feasibility study. J Clin Oncol 1997 ; 15 : 1080-6.
49. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan - induced delayed - onset diarrhea in patients with advanced colorectal cancer : a prospective assessment. J Clin Oncol 1998 ; 16 : 2745-51.
50. Sakata Y, Suzuki, H, Kamataki T. Preventive effect of TJ-14, a kampo medicine, on diarrhea induced by irinotecan hydrochloride. Jpn J Cancer Chemother (Gan To Kagaku Ryoho) 1994 ; 21 : 1241-4.
51. Takasuna K, Hagiwara T, Hirohashi M, at al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT11) in rats. Cancer Res 1996 ; 56 : 3752-7.
52. Boisseau M, Guichard S, Canal P, Bugat R. Irinotecan (CPT11) : current status and perspectives. Expert Opinion on Investigational Drugs 1996 ; 5 : 613-26.
53. Rothenberg ML. CPT11 : an original spectrum of clinical activity. Semin Oncol 1996 ; 23 (1 suppl. 3) ; 21-6.
54. Armand JP, Ducreux M, Mahjoubi M, et al. CPT11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995 ; 31A : 1283-7.
55. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT11, a new camptothecin derivative, in metastatic colorectal cancer. CPT11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993 ; 11 : 909-13.
56. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996 ; 14 : 709-15.
57. Shimada Y, Rougier P, Pitot H. Efficacy of CPT11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 1996 ; 32A suppl. 3 : S13-7.
58. Rothenberg ML, Eckardt JR, Burris HA 3rd, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996 ; 14 : 1128-35.
59. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997 ; 15 : 251-60.
60. Fukuoka M, Nitani H, Suzuki A, et al. A phase II study of CPT11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992 ; 10 : 16-20.
61. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT11 : a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992 ; 10 : 1225-9.
62. Masuda N, Fukuoka M, Takada M, et al. CPT11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992 ; 10 : 1775-80.
63. Chevallier B, Lhomme C, Dieras V, et al. Phase II trial of CPT11 in advanced cervical carcinoma. Proc Am Soc Clin Oncol 1995 ; 14 : 267 (abstract).
64. Potkul RK, Price VT, Bailey H, et al. Irinotecan (CPT11) in advanced squamous cell carcinoma of the cervix (Phase II). Proc Am Soc Clin Oncol 1995 ; 14 : 279 (abstract).
65. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997 ; 15 : 625-31.
66. Sakata Y, Shimada Y, Yoshino M, et al. A late phase II study of CPT11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. Gan To Kagaku Ryoho 1994 ; 21 : 1039-46.
67. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995 ; 6 : 129-32.
68. Futatsuki K, Wakui A, Nakao I, et al. A late phase II study of irinotecan hydrochloride (CPT11) in advanced gastric cancer. CPT11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994 ; 21 : 1033-8.
69. Bonneterre J. Topoisomerase I inhibitors. Review of clinical phase II trials of irinotecan (CPT11) and topotecan. Bull Cancer 1995 ; 82 : 623-8.
70. Taguchi T, Tominaga T, Ogawa M, et al. A late phase II study of CPT11 (irinotecan) in advanced breast cancer, CPT11 Study Group on Breast Cancer. Jpn. J. Cancer Chemother. Gan To Kagaku Ryoho 1994 ; 21 : 1017-24.
71. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT11: a new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 1990 ; 8 : 1907-12.
72. Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT11). CPT11 Study Group on Hematological Malignancy. Br J Cancer 1994 ; 70 : 771-4.
73. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT11 in the mouse. Cancer Res 1990 ; 50 : 1715-20.
74. Barilero I, Gandia D, Armand JP, et al. Simultaneous determination of the camptothecin analogue CPT11 and its active metabolite SN38 by high-performance liquid chromatography - Application to plasma pharmacokinetic studies in cancer patients. J Chromatogr Biomed Appl 1992 ; 575 : 275-80.
75. Akimoto K, Goto A, Ohya K. Selective and sensitive determination of lactone and hydroxy acid forms of camptothecin and two derivatives (CPT11 and SN38) by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1991 ; 588 : 165-70.
76. Rivory LP, Robert J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT11, and its metabolite SN38 in plasma. J Chromatogr Biomed Appl 1994 ; 661 : 133-41.
77. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B Biomed Appl 1997 ; 691 : 161-71.
78. Sumiyoshi H, Fujiwara Y, Ohune T, et al. High-performance liquid chromatographic determination of irinotecan (CPT11) and its active metabolite (SN38) in human plasma. J Chromatogr B Biomed Appl 1995 ; 670 : 309-16.
79. Sasaki Y, Yoshida Y, Sudoh K, et al. Pharmacological correlation between total drug concentration and lactones of CPT11 and SN38 in patients treated with CPT11. Jpn J Cancer Res 1995 ; 86 : 111-6.
80. Sasaki Y, Hakusui H, Mizuno S, et al. A pharmacokinetic and pharmacodynamic analysis of CPT11 and its active metabolite SN38. Jpn J Cancer Res (Gann) 1995 ; 86 : 101-10.
81. Rivory LP, Chatelut E, Canal P, et al. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT11) and of its metabolite SN38 in patients. Cancer Res 1994 ; 54 : 6330-3.
82. Tsuji T, Kaneda N, Kado K, et al. CPT11 converting enzyme from rat serum : purification and some properties. J Pharmacobiodyn 1991 ; 14 : 341-9.
83. Satoh T, Hosokawa M, Atsumi R, et al. Metabolic activation of CPT11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino)carbonyloxy camptothecin, a novel antitumor agent, by carboxyesterase. Biol Pharm Bull 1994 ; 17 : 662-4.
84. Rivory LP, Bowles MR, Robert J, et al. Conversion of irinotecan (CPT11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN38), by human liver carboxyesterase. Biochem Pharmacol 1996 ; 52 : 1103-11.
85. Haaz MC, Rivory LP, Riché C, Robert J. The transformation of irinotecan (CPT11) to its active metabolite SN38 by human liver microsomes - Differential hydrolysis for the lactone and carboxylate forms. Naunyn-Schmiedeberg's Arch. Pharmacol 1997 ; 356 : 257-62.
86. Chabot GG, Abigerges D, Catimel G, et al. Population pharmacokinetics and pharmacodynamics of Irinotecan (CPT11) and active metabolite SN38 during phase I trials. Ann Oncol 1995 ; 6 : 141-51.
87. Rivory LP, Robert J. Identification and kinetics of a beta-glucuronide metabolite of SN38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995 ; 36 : 176-9.
88. Haaz MC, Rivory L, Jantet S, et al. Glucuronidation of SN38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 1997 ; 80 : 91-6.
89. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans : correlation of glucuronidation with diarrhea. Cancer Res 1994 ; 54 : 3723-5.
90. Rivory LP, Riou JF, Haaz MC, et al. Identification and properties of a major plasma metabolite of irinotecan (CPT11) isolated from the plasma of patients. Cancer Res 1996 ; 56 : 3689-94.
91. Haaz MC, Rivory L, Riché C, Vernillet, Robert, J. Metabolism of irinotecan by human hepatic microsomes : participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998 ; 58 : 468-72.
92. Lokiec F, Monegier du Sorbier B, Sanderink GJ. Irinotecan (CPT11) metabolites in human bile and urine. Clin Cancer Res 1996 ; 2 : 1943-9.
93. Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT11) in aqueous solutions : identification of fluorescent products and influence of solution composition. J Pharmaceutical Sc 1997 ; 86 : 1410-6.
94. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993 ; 68 : 777-82.
95. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994 ; 12 : 1833-41.
96. Canal P, Gay C, Dezeuze A, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 1996 ; 14 : 2688-95.
97. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic inter-relationships of irinotecan (CPT11) and its 3 major plasma metabolites in patients enrolled in phase I-II trials. Clin Cancer Res 1997 ; 3 : 1261-6.
98. Iyer L, King C, Tephly T, et al. UGT isoform 1.1 (UGT*1.1) glucuronidates SN38, the active metabolite of irinotecan. Proc Am Soc Clin Oncol 1997 ; 16 : 201a (abstract 707).
99. Unpublished data on file, Rhône-Poulenc Roter SA Antony, France.
100. Burke TG, Mi Z. The structural basis of camptothecin interactions with human serum albumin : impact on drug stability. J Med Chem 1994 ; 37 : 40-6.
101. Burris H, Dietz A, Eckardt J, et al. A phase I trial to evaluate orally administered irinotecan HCl (CPT11) given daily X 5 every 3 weeks in patients with refractory malignancies. Proc Amer Soc Clin Oncol 1996 ; 15 : 489 (abstract).
102. Lokiec F, Canal P, Gay C, et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995 ; 36 : 79-82.
103. Chabot GG. Factors involved in clinical pharmacology variability in oncology (review). Anticancer Res 1994 ; 14 : 2269-72.
104. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997 ; 15 : 1502-10.
105. Gupta E, Wang X, Ramirez J, et al. Modulation of glucuronidation of SN38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 1997 ; 39 : 440-4.
106. Gupta E, Safa AR, Wang X, et al. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 1996 ; 56 : 1309-14.
107. Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT11 and fluorouracil : alteration of the pharmacokinetics of CPT11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994 ; 86 : 1096-8.
108. Grossin F, Barbault H, Benhammouda A, et al. A phase I pharmacokinetics study of concomitant CPT11 and 5FU combination. Proc Am Assoc Cancer Res 1996 ; 37 : 168 (abstract 1156).
109. Saltz LB, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996 ; 14 : 2959-67.
110. Karato A, Sasaki Y, Shiraishi J, et al. Pharmacokinetic study in the dose escalation study of CPT11 and VP-16. Proc Am Assoc Cancer Res 1993 ; 34 (abstract 2325).
111. Couteau C, Lokiec F, Vernillet L, et al. Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors. Proc Am Soc Clin Oncol 1997 ; 16 : 202a (abstract 709).
112. Kudoh S, Fukuoka M, Masuda N, et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 1995 ; 86 : 406-13.
113. Mick R, Gupta E, Vokes EE, et al. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics : prediction of biliary index and intestinal toxicity. J Clin Oncol 1996 ; 14 : 2012-9.
114. Chabot GG. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN38. Cancer Cbemother Pharmacol 1995 ; 36 : 463-72.
115. Nakashima H, Lieberman, R, Karato A, et al. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT11) : implication for area under the concentration-time curve monitoring. Ther Drug Monit 1995 ; 17 : 221-9.
116. Sasaki Y, Mizuno S, Fujii H, et al. A limited sampling model for estimating pharmacokinetics of CPT11 and its metabolite SN38. Jpn J Cancer Res 1995 ; 86 : 117-23.
117. Yamamoto N, Ramura T, Kararo A, et al. CPT11 : population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer. Jpn J Cancer Res 1994 ; 85 : 972-7.
118. Chabot GG. Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 1997 ; 33 : 245-59.